- Home
- VERU vs CHRS Comparison
VERU vs CHRS Comparison
Compare VERU & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- CHRS
- Stock Information
- Founded
- VERU 1971
- CHRS 2010
- Country
- VERU United States
- CHRS United States
- Employees
- VERU N/A
- CHRS N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VERU Health Care
- CHRS Health Care
- Exchange
- VERU Nasdaq
- CHRS Nasdaq
- Market Cap
- VERU 85.5M
- CHRS 102.0M
- IPO Year
- VERU 1990
- CHRS 2014
- Fundamental
- Price
- VERU $0.49
- CHRS $0.97
- Analyst Decision
- VERU Strong Buy
- CHRS Buy
- Analyst Count
- VERU 2
- CHRS 3
- Target Price
- VERU $4.00
- CHRS $4.68
- AVG Volume (30 Days)
- VERU 1.4M
- CHRS 1.3M
- Earning Date
- VERU 08-07-2025
- CHRS 08-07-2025
- Dividend Yield
- VERU N/A
- CHRS N/A
- EPS Growth
- VERU N/A
- CHRS N/A
- EPS
- VERU N/A
- CHRS N/A
- Revenue
- VERU $16,886,419.00
- CHRS $272,251,000.00
- Revenue This Year
- VERU N/A
- CHRS N/A
- Revenue Next Year
- VERU N/A
- CHRS $99.43
- P/E Ratio
- VERU N/A
- CHRS N/A
- Revenue Growth
- VERU 134.43
- CHRS 19.87
- 52 Week Low
- VERU $0.45
- CHRS $0.66
- 52 Week High
- VERU $1.42
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- VERU 35.42
- CHRS 57.25
- Support Level
- VERU $0.49
- CHRS $0.88
- Resistance Level
- VERU $0.61
- CHRS $1.15
- Average True Range (ATR)
- VERU 0.04
- CHRS 0.07
- MACD
- VERU -0.01
- CHRS 0.01
- Stochastic Oscillator
- VERU 2.27
- CHRS 45.95
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.